7/7/2009

The FDA asked Protalix to submit a treatment protocol for prGCD, its experimental Gaucher's disease drug, in light of a manufacturing problem that is expected to reduce the supply of Genzyme's Cerezyme. Protalix and the agency are reportedly discussing parameters to increase patients' access to prGCD.

Related Summaries